This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 4.71% and 0.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What is in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $57.81, moving -0.45% from the previous trading session.
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $58.36, moving +1.14% from the previous trading session.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
by Zacks Equity Research
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx
by Zacks Equity Research
The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
by Zacks Equity Research
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.07, marking a +0.02% move from the previous day.
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
The Zacks Analyst Blog Highlights: NextEra Energy, Raytheon, Bristol-Myers Squibb, Williams Companies and Occidental Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NextEra Energy, Raytheon, Bristol-Myers Squibb, Williams Companies and Occidental Petroleum
Top Stock Reports for NextEra, Raytheon & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including NextEra Energy, Inc. (NEE), Raytheon Technologies Corporation (RTX), and Bristol-Myers Squibb Company (BMY).
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
by Zacks Equity Research
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
Bristol Myers (BMY) UC Candidate Fails in Phase II Study
by Zacks Equity Research
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.01, marking a -0.3% move from the previous day.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH